Literature DB >> 11527800

Clinical and serological follow-up of patients with human granulocytic ehrlichiosis in Slovenia.

S Lotric-Furlan1, T Avsic-Zupanc, M Petrovec, W L Nicholson, J W Sumner, J E Childs, F Strle.   

Abstract

An evaluation of the clinical outcome and the duration of the antibody response of patients with human granulocytic ehrlichiosis (HGE) was undertaken in Slovenia. Adult patients with a febrile illness occurring within 6 weeks of a tick bite were classified as having probable or confirmed HGE based on the outcome of serological or PCR testing. Thirty patients (median age, 44 years) were enrolled, and clinical evaluations and serum collection were undertaken at initial presentation and at 14 days, 6 to 8 weeks, and 3 to 4, 6, 12, 18, and 24 months. An indirect immunofluorescence assay (IFA) was performed, and reciprocal titers of > or =128 were interpreted as positive. Patients presented a median of 4 days after the onset of fever and were febrile for a median of 7.5 days; four (13.3%) received doxycycline. Seroconversion was observed in 3 of 30 (10.0%) patients, and 25 (83.3%) showed >4-fold change in antibody titer. PCR results were positive in 2 of 3 (66.7%) seronegative patients but in none of 27 seropositive patients at the first presentation. IFA antibody titers of > or =128 were found in 14 of 29 (48.3%), 17 of 30 (56.7%), 13 of 30 (43.4%), and 12 of 30 (40.0%) patients 6, 12, 18, and 24 months after presentation, respectively. Patients reporting additional tick bites during the study had significantly higher antibody titers at most time points during follow-up. No long-term clinical consequences were found during follow-up.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11527800      PMCID: PMC96168          DOI: 10.1128/CDLI.8.5.899-903.2001

Source DB:  PubMed          Journal:  Clin Diagn Lab Immunol        ISSN: 1071-412X


  24 in total

1.  A further case of acute human granulocytic ehrlichiosis in Slovenia.

Authors:  H Laferl; W Hogrefe; T Köck; H Pichler
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1999-05       Impact factor: 3.267

2.  Reinfection with the agent of human granulocytic ehrlichiosis.

Authors:  H W Horowitz; M Aguero-Rosenfeld; J S Dumler; D F McKenna; T C Hsieh; J Wu; I Schwartz; G P Wormser
Journal:  Ann Intern Med       Date:  1998-09-15       Impact factor: 25.391

3.  Human granulocytic ehrlichiosis in New York.

Authors:  B J Wallace; G Brady; D M Ackman; S J Wong; G Jacquette; E E Lloyd; G S Birkhead
Journal:  Arch Intern Med       Date:  1998-04-13

4.  Case definitions for infectious conditions under public health surveillance. Centers for Disease Control and Prevention.

Authors: 
Journal:  MMWR Recomm Rep       Date:  1997-05-02

5.  Human granulocytic ehrlichiosis: a case series from a medical center in New York State.

Authors:  M E Aguero-Rosenfeld; H W Horowitz; G P Wormser; D F McKenna; J Nowakowski; J Muñoz; J S Dumler
Journal:  Ann Intern Med       Date:  1996-12-01       Impact factor: 25.391

6.  An indirect immunofluorescence assay using a cell culture-derived antigen for detection of antibodies to the agent of human granulocytic ehrlichiosis.

Authors:  W L Nicholson; J A Comer; J W Sumner; C Gingrich-Baker; R T Coughlin; L A Magnarelli; J G Olson; J E Childs
Journal:  J Clin Microbiol       Date:  1997-06       Impact factor: 5.948

7.  Human disease in Europe caused by a granulocytic Ehrlichia species.

Authors:  M Petrovec; S Lotric Furlan; T A Zupanc; F Strle; P Brouqui; V Roux; J S Dumler
Journal:  J Clin Microbiol       Date:  1997-06       Impact factor: 5.948

8.  Fever, leukopenia, and thrombocytopenia in a patient with acute Lyme borreliosis were due to human granulocytic ehrlichiosis.

Authors:  R Weber; N Pusterla; M Loy; H Lutz
Journal:  Clin Infect Dis       Date:  1998-01       Impact factor: 9.079

9.  Human granulocytic ehrlichiosis in the upper Midwest United States. A new species emerging?

Authors:  J S Bakken; J S Dumler; S M Chen; M R Eckman; L L Van Etta; D H Walker
Journal:  JAMA       Date:  1994-07-20       Impact factor: 56.272

10.  Clinical and laboratory characteristics of human granulocytic ehrlichiosis.

Authors:  J S Bakken; J Krueth; C Wilson-Nordskog; R L Tilden; K Asanovich; J S Dumler
Journal:  JAMA       Date:  1996-01-17       Impact factor: 56.272

View more
  12 in total

1.  Contribution of polymorphisms in ankA, gltA, and groESL in defining genetic variants of Anaplasma phagocytophilum.

Authors:  Sanjay K Shukla; Vijay Aswani; Patrick J Stockwell; Kurt D Reed
Journal:  J Clin Microbiol       Date:  2007-05-16       Impact factor: 5.948

2.  Genetic variants of Anaplasma phagocytophilum infecting dogs in Western Washington State.

Authors:  Florence M Poitout; Joanne K Shinozaki; Patrick J Stockwell; Cynthia J Holland; Sanjay K Shukla
Journal:  J Clin Microbiol       Date:  2005-02       Impact factor: 5.948

3.  Detection and identification of Ehrlichia spp. in ticks collected in Tunisia and Morocco.

Authors:  M'Hammed Sarih; Youmna M'Ghirbi; Ali Bouattour; Lise Gern; Guy Baranton; Danièle Postic
Journal:  J Clin Microbiol       Date:  2005-03       Impact factor: 5.948

4.  Analysis of genetic identity of North American Anaplasma phagocytophilum strains by pulsed-field gel electrophoresis.

Authors:  J S Dumler; K M Asanovich; J S Bakken
Journal:  J Clin Microbiol       Date:  2003-07       Impact factor: 5.948

5.  Cytokine gene expression by peripheral blood leukocytes in horses experimentally infected with Anaplasma phagocytophila.

Authors:  Hyung-Yong Kim; Jason Mott; Ning Zhi; Tomoko Tajima; Yasuko Rikihisa
Journal:  Clin Diagn Lab Immunol       Date:  2002-09

6.  First documented case of human granulocytic ehrlichiosis in Austria.

Authors:  Gernot Walder; Barbara Falkensammer; Johannes Aigner; Gerhard Tiwald; Manfred P Dierich; Reinhard Würzner; Peter Lechleitner
Journal:  Wien Klin Wochenschr       Date:  2003-04-30       Impact factor: 1.704

7.  Roles of p38 mitogen-activated protein kinase, NF-kappaB, and protein kinase C in proinflammatory cytokine mRNA expression by human peripheral blood leukocytes, monocytes, and neutrophils in response to Anaplasma phagocytophila.

Authors:  Hyung-Yong Kim; Yasuko Rikihisa
Journal:  Infect Immun       Date:  2002-08       Impact factor: 3.441

8.  Epidemiological, clinical and laboratory characteristics of patients with human granulocytic anaplasmosis in Slovenia.

Authors:  Stanka Lotric-Furlan; Tereza Rojko; Miroslav Petrovec; Tatjana Avsic-Zupanc; Franc Strle
Journal:  Wien Klin Wochenschr       Date:  2006-11       Impact factor: 2.275

9.  Value of PCR, Serology, and Blood Smears for Human Granulocytic Anaplasmosis Diagnosis, France.

Authors:  Yves Hansmann; Benoit Jaulhac; Pierre Kieffer; Martin Martinot; Elisabeth Wurtz; Régis Dukic; Geneviève Boess; André Michel; Christophe Strady; Jean François Sagez; Nicolas Lefebvre; Emilie Talagrand-Reboul; Xavier Argemi; Sylvie De Martino
Journal:  Emerg Infect Dis       Date:  2019-05       Impact factor: 6.883

10.  Human granulocytic ehrlichiosis in Estonia.

Authors:  Tina Prükk; Kylliki Ainsalu; Ene Laja; Ada Aigro
Journal:  Emerg Infect Dis       Date:  2003-11       Impact factor: 6.883

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.